Cargando…

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

SIMPLE SUMMARY: Cyclin-dependent kinase (CDK) 4/6 inhibitors, in combination with endocrine therapies, are now the standard of care for patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Despite the effectiveness of CDK4/6 inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Kamal, Katuwal, Nar Bahadur, Park, Nahee, Hur, Jin, Cho, Young Bin, Kim, Seung Ki, Lee, Seung Ah, Kim, Isaac, Lee, Seung-Ryeol, Moon, Yong Wha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750394/ https://www.ncbi.nlm.nih.gov/pubmed/35008374 http://dx.doi.org/10.3390/cancers14010210

Ejemplares similares

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics
por: Pandey, Kamal, et al.
Publicado: (2021)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model
por: Park, Nahee, et al.
Publicado: (2020)

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
por: Jeong, Yeong Gyu, et al.
Publicado: (2023)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
por: Calucică, Daniela Maria, et al.
Publicado: (2022)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
por: Katuwal, Nar Bahadur, et al.
Publicado: (2023)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
por: Gebbia, Vittorio, et al.
Publicado: (2023)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
por: Mlinarić, Zvonimir, et al.
Publicado: (2022)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
por: Wender, Isabella O., et al.
Publicado: (2020)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
por: Law, Ernest H, et al.
Publicado: (2023)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
por: Pandey, Kamal, et al.
Publicado: (2019)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling
por: Phi, Ji Hoon, et al.
Publicado: (2015)

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
por: Ji, Wenfei, et al.
Publicado: (2019)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
por: MAYLINA, Leni, et al.
Publicado: (2022)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
por: Mao, Yan, et al.
Publicado: (2023)

Isothermal and temperature-cycling retrogradation of high-amylose corn starch: Impact of sonication on its structural and retrogradation properties
por: Han, Kyu Tae, et al.
Publicado: (2021)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
por: Park, Min Ho, et al.
Publicado: (2020)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

Capsule Endoscopy: Pitfalls and Approaches to Overcome
por: Kim, Seung Han, et al.
Publicado: (2021)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Cyclin-Dependent Kinase Inhibitor 2A is a Key Regulator of Cell Cycle Arrest and Senescence in Endothelial Colony-Forming Cells in Moyamoya Disease
por: Choi, Seung Ah, et al.
Publicado: (2023)

Cycling kinematics in healthy adults for musculoskeletal rehabilitation guidance
por: Yum, Haeun, et al.
Publicado: (2021)

Overcoming osteoporosis and beyond: Locomotive syndrome or dysmobility syndrome
por: Yi, Hyon-Seung, et al.
Publicado: (2018)

Significance of the serum CA-125 level in intrauterine insemination cycles
por: Choe, Seung Ah, et al.
Publicado: (2011)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u2tlasli4cqa8lba6s2t3t40j2